← Leaderboards
Kenneth L Rock
Univ Of Massachusetts Med Sch Worcester
$34,501,220
Attributed
$34,501,220
Total exposure
17
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$39,788,911 · 18
By mechanism
R01$28,217,895 · 12
P01$7,592,417 · 3
R37$2,399,776 · 1
RC1$1,299,794 · 1
R56$279,029 · 1
Top collaborators
No co-investigators on record.
Most similar at Univ Of Massachusetts Med Sch Worcester
Same institution · by research overlap
- Vanni Bucci$2,397,148
- Beth A McCormick$17,465,257
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsImmune SystemResponseAntigen PresentationDendritic CellsLeadPreventPeptidesT-LymphocyteImmune ResponseInsightMalignant NeoplasmsIn VivoBasePathway InteractionsVirusTissuesMacrophageAbbreviationsImmunologic SurveillanceMolecularGrantAntigensAntigen-Presenting Cells
Grant awards (91)
Novel histone-binding C-type lectin receptors and their role in sterile inflammation and tissue injury$576,048
R01 · FY2025 · AI · contact PI
Role of Tspan5 in MHC I antigen presentation and cancer immune evasion$492,997
R01 · FY2025 · AI · contact PI
Novel histone-binding C-type lectin receptors and their role in sterile inflammation and tissue injury$593,865
R01 · FY2024 · AI · contact PI
Role of IRF2 in cancer immune evasion and immunotherapy$553,729
R01 · FY2024 · CA · contact PI
Role of Tspan5 in MHC I antigen presentation and cancer immune evasion$494,409
R01 · FY2024 · AI · contact PI
Novel histone-binding C-type lectin receptors and their role in sterile inflammation and tissue injury$593,865
R01 · FY2023 · AI · contact PI
Role of IRF2 in cancer immune evasion and immunotherapy$571,214
R01 · FY2023 · CA · contact PI
Role of Tspan5 in MHC I antigen presentation and cancer immune evasion$495,793
R01 · FY2023 · AI · contact PI
Mechanisms of cross-presenting antigens in phagosomes on MHC I molecules to stimulate CD8 T lymphocyte responses$418,750
R01 · FY2023 · AI · contact PI
Role of IRF2 in cancer immune evasion and immunotherapy$571,214
R01 · FY2022 · CA · contact PI
Role of Tspan5 in MHC I antigen presentation and cancer immune evasion$497,167
R01 · FY2022 · AI · contact PI
Mechanisms of cross-presenting antigens in phagosomes on MHC I molecules to stimulate CD8 T lymphocyte responses$418,750
R01 · FY2022 · AI · contact PI
Role of IRF2 in cancer immune evasion and immunotherapy$582,872
R01 · FY2021 · CA · contact PI
Role of Tspan5 in MHC I antigen presentation and cancer immune evasion$515,375
R01 · FY2021 · AI · contact PI
Role of Clec2d-DAMP interactions in the pathophysiology of tissue injury and sepsis$480,896
R01 · FY2021 · AI · contact PI
Mechanisms of cross-presenting antigens in phagosomes on MHC I molecules to stimulate CD8 T lymphocyte responses$418,750
R01 · FY2021 · AI · contact PI
Role of IRF2 in cancer immune evasion and immunotherapy$582,872
R01 · FY2020 · CA · contact PI
Role of Clec2d-DAMP interactions in the pathophysiology of tissue injury and sepsis$480,896
R01 · FY2020 · AI · contact PI
Mechanisms of cross-presenting antigens in phagosomes on MHC I molecules to stimulate CD8 T lymphocyte responses$418,750
R01 · FY2020 · AI · contact PI
Elucidation of the role of 2 novel cross presentation genes$418,750
R01 · FY2020 · AI · contact PI
Role of Clec2d-DAMP interactions in the pathophysiology of tissue injury and sepsis$480,896
R01 · FY2019 · AI · contact PI
Mechanisms of cross-presenting antigens in phagosomes on MHC I molecules to stimulate CD8 T lymphocyte responses$418,750
R01 · FY2019 · AI · contact PI
Elucidation of the role of 2 novel cross presentation genes$418,750
R01 · FY2019 · AI · contact PI
Mechanisms of positive and negative thymic selection of CD8 T cells$418,750
R01 · FY2019 · AI · contact PI
Role of Clec2d-DAMP interactions in the pathophysiology of tissue injury and sepsis$480,908
R01 · FY2018 · AI · contact PI
Mechanisms of positive and negative thymic selection of CD8 T cells$418,750
R01 · FY2018 · AI · contact PI
Elucidation of the role of 2 novel cross presentation genes$418,750
R01 · FY2018 · AI · contact PI
Elucidation of the role of 2 novel cross presentation genes$418,750
R01 · FY2017 · AI · contact PI
Role of Clec2d-DAMP interactions in the pathophysiology of tissue injury and sepsis$418,750
R01 · FY2017 · AI · contact PI
Mechanisms of positive and negative thymic selection of CD8 T cells$418,750
R01 · FY2017 · AI · contact PI
Elucidation of the role of 2 novel cross presentation genes$418,750
R01 · FY2016 · AI · contact PI
Mechanisms of positive and negative thymic selection of CD8 T cells$418,750
R01 · FY2016 · AI · contact PI
Mechanisms of positive and negative thymic selection of CD8 T cells$302,373
R01 · FY2015 · AI · contact PI
Mechanisms of positive and negative thymic selection of CD8 T cells$279,029
R56 · FY2014 · AI · contact PI
Immunobiology of CTL Responses to Exogenous Antigen$378,883
R01 · FY2013 · AI · contact PI
How cell death and sterile particulates stimulate inflammation and disease$378,883
R01 · FY2013 · AI · contact PI
Immunobiology of MHC Restriction of T-Cells$378,883
R01 · FY2013 · AI · contact PI
How cell death and sterile particulates stimulate inflammation and disease$403,066
R01 · FY2012 · AI · contact PI
Immunobiology of CTL Responses to Exogenous Antigen$403,066
R01 · FY2012 · AI · contact PI
Immunobiology of MHC Restriction of T-Cells$403,066
R01 · FY2012 · AI · contact PI
How cell death and sterile particulates stimulate inflammation and disease$403,066
R01 · FY2011 · AI · contact PI
Immunobiology of CTL Responses to Exogenous Antigen$403,066
R01 · FY2011 · AI · contact PI
Immunobiology of MHC Restriction of T-Cells$403,066
R01 · FY2011 · AI · contact PI
Mitigating radiodermatitis by blocking IL-1-dependent neutrophilic inflammation$522,603
RC1 · FY2010 · AI · contact PI
Immunobiology of CTL Responses to Exogenous Antigen$407,138
R01 · FY2010 · AI · contact PI
How cell death and sterile particulates stimulate inflammation and disease$407,034
R01 · FY2010 · AI · contact PI
Immunobiology of MHC Restriction of T-Cells$406,622
R01 · FY2010 · AI · contact PI
Immunobiology of CTL Responses to Exogenous Antigen$410,000
R01 · FY2009 · AI · contact PI
How cell death and sterile particulates stimulate inflammation and disease$409,896
R01 · FY2009 · AI · contact PI
Immunobiology of MHC Restriction of T-Cells$409,479
R01 · FY2009 · AI · contact PI
Adjuvants and Toll-like Receptors in Vaccine Development$1,059,777
P01 · FY2008 · AI · contact PI
Mitigating radiodermatitis by blocking IL-1-dependent neutrophilic inflammation$777,191
RC1 · FY2008 · AI · contact PI
Endogenous Adjuvants in Viral Immunity and Vaccines$431,579
P01 · FY2008 · AI · contact PI
Immunobiology of CTL Responses to Exogenous Antigens$377,879
R01 · FY2008 · AI · contact PI
IMMUNOBIOLOGY OF MHC RESTRICTION OF T CELLS$81,198
R37 · FY2008 · AI · contact PI
Adjuvants and Toll-like Receptors in Vaccine Development$1,049,837
P01 · FY2007 · AI · contact PI
Endogenous Adjuvants in Viral Immunity and Vaccines$427,532
P01 · FY2007 · AI · contact PI
Immunobiology of CTL Responses to Exogenous Antigens$385,198
R01 · FY2007 · AI · contact PI
IMMUNOBIOLOGY OF MHC RESTRICTION OF T CELLS$301,521
R37 · FY2007 · AI · contact PI
Project 4: Inducing Antigen specific Tolerance Using APCs$141,083
P01 · FY2007 · DK · contact PI
Ajuvants and Toll-like Receptors in vaccine Development$1,050,486
P01 · FY2006 · AI · contact PI
Endogenous Adjuvants in Viral Immunity and Vaccines$438,094
P01 · FY2006 · AI · contact PI
Immunobiology of CTL Responses to Exogenous Antigens$396,398
R01 · FY2006 · AI · contact PI
Immunobiology of Antigen Presenting Cells in Vivo$349,344
R01 · FY2006 · AI · contact PI
IMMUNOBIOLOGY OF MHC RESTRICTION OF T CELLS$310,527
R37 · FY2006 · AI · contact PI
Ajuvants and Toll-like Receptors in vaccine Development$1,041,976
P01 · FY2005 · AI
Endogenous Adjuvants in Viral Immunity and Vaccines$424,333
P01 · FY2005 · AI
Immunobiology of CTL Responses to Exogenous Antigens$405,000
R01 · FY2005 · AI
Immunobiology of Antigen Presenting Cells in Vivo$357,750
R01 · FY2005 · AI
IMMUNOBIOLOGY OF MHC RESTRICTION OF T CELLS$318,000
R37 · FY2005 · AI
Ajuvants and Toll-like Receptors in vaccine Development$1,085,615
P01 · FY2004 · AI
Endogenous Adjuvants in Viral Immunity and Vaccines$442,105
P01 · FY2004 · AI
Immunobiology of CTL Responses to Exogenous Antigens$403,125
R01 · FY2004 · AI
Immunobiology of Antigen Presenting Cells in Vivo$357,750
R01 · FY2004 · AI
IMMUNOBIOLOGY OF MHC RESTRICTION OF T CELLS$318,000
R37 · FY2004 · AI
Antibody Immunotherapy to a Pro-apoptotic Tumor Antigen$283,020
R01 · FY2004 · CA
Immunobiology of Antigen Presenting Cells in Vivo$457,750
R01 · FY2003 · AI
IMMUNOBIOLOGY OF CTL RESPONSES TO EXOGENOUS ANTIGENS$306,751
R01 · FY2003 · AI
Antibody Immunotherapy to a Pro-apoptotic Tumor Antigen$283,020
R01 · FY2003 · CA
IMMUNOBIOLOGY OF MHC RESTRICTION OF T CELLS$259,000
R37 · FY2003 · AI
Immunobiology of Antigen Presenting Cells in Vivo$357,376
R01 · FY2002 · AI
IMMUNOBIOLOGY OF CTL RESPONSES TO EXOGENOUS ANTIGENS$298,958
R01 · FY2002 · AI
Antibody Immunotherapy to a Pro-apoptotic Tumor Antigen$283,020
R01 · FY2002 · CA
IMMUNOBIOLOGY OF MHC RESTRICTION OF T CELLS$263,060
R37 · FY2002 · AI
VACCINE STRATEGIES FOR IMMUNOTHERAPY OF CANCER$244,737
R01 · FY2002 · CA
IMMUNOBIOLOGY OF CTL RESPONSES TO EXOGENOUS ANTIGENS$290,591
R01 · FY2001 · AI
IMMUNOBIOLOGY OF MHC RESTRICTION OF T CELLS$255,397
R37 · FY2001 · AI
VACCINE STRATEGIES FOR IMMUNOTHERAPY OF CANCER$236,245
R01 · FY2001 · CA
IMMUNOBIOLOGY OF MHC RESTRICTION OF T CELLS$293,073
R37 · FY2000 · AI
IMMUNOBIOLOGY OF CTL RESPONSES TO EXOGENOUS ANTIGENS$282,128
R01 · FY2000 · AI
VACCINE STRATEGIES FOR IMMUNOTHERAPY OF CANCER$228,002
R01 · FY2000 · CA